Last reviewed · How we verify
Herceptin SC [trastuzumab]
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death. Used for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings), HER2-positive metastatic gastric cancer.
At a glance
| Generic name | Herceptin SC [trastuzumab] |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | HER2-targeted monoclonal antibody |
| Target | HER2 (human epidermal growth factor receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Trastuzumab targets human epidermal growth factor receptor 2 (HER2), a protein overexpressed in certain cancers. By binding to HER2, it prevents ligand-induced signaling, inhibits cell proliferation, and recruits immune cells to destroy HER2-positive tumor cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Approved indications
- HER2-positive metastatic breast cancer
- HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings)
- HER2-positive metastatic gastric cancer
Common side effects
- Cardiac dysfunction / left ventricular ejection fraction (LVEF) decline
- Infusion reactions
- Nausea
- Diarrhea
- Fatigue
- Headache
- Vomiting
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Herceptin SC [trastuzumab] CI brief — competitive landscape report
- Herceptin SC [trastuzumab] updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI